Rheumatology and Immunology

The Department of Rheumatology and Immunology has long been engaged in the diagnosis and treatment of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Sjögren syndrome, as well as research into their pathogenesis. The discipline is a domestic leader in the clinical care and research of adult-onset Still’s disease and antiphospholipid syndrome (SLE subtype). In 2020, it became a member of the International Antiphospholipid Syndrome Research Collaboration Group and, in collaboration with the Department of Laboratory Medicine, became one of the six core laboratories (Core-lab) in the world, participating in the establishment of international APS diagnostic criteria and methods. Since the department was established, the team has led multiple research projects, including subprojects of the “14th Five-Year” National Key R&D Program, the National Natural Science Foundation of China, the Shanghai “Medical New Star” program, the Shanghai Young Talents Sail Program, and research fund projects of the Shanghai Municipal Commission of Science and Technology, the Shanghai Municipal Education Commission, and the Shen Kang Hospital Development Center; it has published more than 70 SCI papers in journals including NEJM, BMJ, Lancet Rheumatology, Science, and others. The discipline has joined forces with other nationally leading departments of Ruijin Hospital to establish a multidisciplinary diagnosis and treatment model, build Ruijin Rheumatology’s profile in the diagnosis and treatment of difficult and critical illnesses, and rank 6th nationwide in the 2022 Fudan University China Hospital Specialty Reputation Ranking. The Department of Rheumatology and Immunology of Ruijin Hospital is a clinically and scientifically oriented team with a well-structured echelon, unity, drive, and strong fighting capacity.